Redefiniendo el plan: nuevas vías oncogénicas y nuevos paradigmas en leucemias agudas y crónicas

Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissu. En: WHO classification of tumours of haematopoietic and lymphoid tissues. Fourth ed. Lyon, France: International Agency for Research on Cancer; 2008.

Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau M.M. Le, Bloomfield CD, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-406.

https://doi.org/10.1182/blood-2016-03-643544

Thomas X, Blinatumomab:. a new era of treatment for adult ALL? Lancet Oncol [Internet]. 2015;16:6-7. Elsevier Ltd, Disponible en: http://linkinghub.elsevier.com/retrieve/pii/S1470204514711830

https://doi.org/10.1016/S1470-2045(14)71183-0

Litzow MR. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book [Internet]. 2013:294-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23714527

https://doi.org/10.1200/EdBook_AM.2013.33.294

Hoelzer D, Gökbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev [Internet]. 2012;26:25-32. Elsevier B.V., [consultado el 4 de abril de 2014], Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21958552

https://doi.org/10.1016/j.blre.2011.08.001

Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat. Rev Cancer [Internet]. 2010;10:23-36 [consultado el 14 de enero de 2014], Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2972637&tool=pmcentrez&rendertype=abstract

https://doi.org/10.1038/nrc2765

Kong S, Dong H, Song J, Prabhakar BS, Qiu Q, Lin Z, et al. Deleted in Breast Cancer 1 Suppresses B Cell Activation through RelB and Is Regulated by IKK α Phosphorylation. 2016.

https://doi.org/10.4049/jimmunol.1500713

Cruz Rodríguez N, Combita AL, Enciso LJ, Quijano SM, Pinzon PL, Lozano OC, et al. High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia. 2016:1-14.

https://doi.org/10.1186/s13046-016-0333-z

Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer [Internet]. 2004;101:2788-801 [consultado el 14 de enero de 2014], Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/15481055

https://doi.org/10.1002/cncr.20668

Enciso LJ, Carre˜no JA, Leticia M, Bermúdez CD, Barrientos MA, Samudio I, et al. Tratamiento de rescate de leucemia aguda refractaria o en recaída con el régimen IDA-FLAG : experiencia en la rutina de los servicios. Rev Colomb Cancerol. 2014;18(2.).

https://doi.org/10.1016/j.rccan.2014.04.001

Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol [Internet]. 2014:5766 [consultado el 22 de diciembre de 2014]; Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25524800.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol [Internet]. 2011;29:2493-8 [consultado el 26 de marzo de 2014], Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21576633

https://doi.org/10.1200/JCO.2010.32.7270

Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol [Internet]. 2013;5 Suppl 1:5-11. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3650887&tool=pmcentrez&rendertype=Abstract

https://doi.org/10.2147/CPAA.S42689

Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res [Internet]. 2011;317:1255-60. Elsevier Inc., Disponible en: http://dx.doi.org/10.1016/j.yexcr.2011.03.010

https://doi.org/10.1016/j.yexcr.2011.03.010

Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler M-E, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood [Internet]. 2012;120:5185-7 [consultado el 20 de enero de 2014], Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23024237

https://doi.org/10.1182/blood-2012-07-441030

Stein A, Topp MS, Goekbuget N, Bargou RC, Dombret H, Fielding AK, et al. Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood [Internet]. 2014;124:965. Disponible en: http://www.bloodjournal.org/content/124/21/965.Abstract

https://doi.org/10.1182/blood.V124.21.965.965

Litzow MR. Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia : the emerging role of blinatumomab. 2014:79-90.

https://doi.org/10.2147/ITT.S37292

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med [Internet]. 2016. NEJMoa1509277. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1509277

https://doi.org/10.1056/NEJMoa1509277